troglitazone has been researched along with Chemical and Drug Induced Liver Injury in 107 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Troglitazone promotes adipocyte differentiation in vitro and increases insulin sensitivity in vivo." | 9.09 | Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. ( Arioglu, E; Duncan-Morin, J; Gottlieb, N; Herion, D; Hoofnagle, J; Kleiner, DE; Lieberman, J; Premkumar, A; Reitman, ML; Reynolds, J; Rother, KI; Sebring, N; Sumner, AE; Taylor, SI, 2000) |
| "Data from cases of liver failure associated with troglitazone use were abstracted and analyzed." | 7.72 | Troglitazone-induced liver failure: a case study. ( Graham, DJ; Green, L; Nourjah, P; Senior, JR, 2003) |
| "A 68-year-old woman, with type 2 diabetes mellitus, hypercholesterolemia, and prior long-term simvastatin therapy, self-resumed troglitazone after running out of metformin." | 7.71 | Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. ( Caldwell, SH; Hespenheide, EE; von Borstel, RW, 2001) |
| "Troglitazone was daily administered for 4 weeks (0, 10 or 30 mg/kg/day, ip)." | 5.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| "Troglitazone is a thiazolidinedione antidiabetic agent with insulin-sensitizing activities that was withdrawn from the market in 2000 due to its association with idiosyncratic hepatotoxicity." | 5.33 | Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. ( Kaneko, S; Katoh, K; Maniratanachote, R; Nakajima, M; Sawazaki, T; Shibata, A; Tokudome, S; Wakasugi, T; Yamamori, I; Yokoi, T, 2005) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 5.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| "Troglitazone promotes adipocyte differentiation in vitro and increases insulin sensitivity in vivo." | 5.09 | Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. ( Arioglu, E; Duncan-Morin, J; Gottlieb, N; Herion, D; Hoofnagle, J; Kleiner, DE; Lieberman, J; Premkumar, A; Reitman, ML; Reynolds, J; Rother, KI; Sebring, N; Sumner, AE; Taylor, SI, 2000) |
| "Recently, we found that profound anorexia observed in a catabolic model induced by chronic glucocorticoid (dexamethasone, Dex) injection could be associated with strong hyperleptinemia." | 3.73 | Troglitazone reduces leptinemia during experimental dexamethasone-induced stress. ( Caldefie-Chézet, F; Enreille-Leger, A; Poulin, A; Vasson, MP, 2005) |
| "Data from cases of liver failure associated with troglitazone use were abstracted and analyzed." | 3.72 | Troglitazone-induced liver failure: a case study. ( Graham, DJ; Green, L; Nourjah, P; Senior, JR, 2003) |
| "A 68-year-old woman, with type 2 diabetes mellitus, hypercholesterolemia, and prior long-term simvastatin therapy, self-resumed troglitazone after running out of metformin." | 3.71 | Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. ( Caldwell, SH; Hespenheide, EE; von Borstel, RW, 2001) |
| " The genotype analysis, however, indicated that the metabolic idiosyncrasy resides in the degradation of but not in the production of the toxic metabolites of troglitazone." | 2.47 | Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. ( Ikeda, T, 2011) |
| "Troglitazone was the first thiazolidinedione antidiabetic agent approved for clinical use in 1997, but it was withdrawn from the market in 2000 due to serious idiosyncratic hepatotoxicity." | 2.46 | Troglitazone. ( Yokoi, T, 2010) |
| " This is further supported by experimental data that demonstrate that troglitazone, alone among the thiazolidinediones, is toxic in hepatocyte cell culture." | 2.42 | Hepatotoxicity of the thiazolidinediones. ( Chandramouli, J; Tolman, KG, 2003) |
| "Troglitazone was designed to combine tocopherol, anti-peroxidant, and thiazolidinedione." | 2.41 | [The development of thiazolidinedione drugs as anti-diabetic agents]. ( Kuzuya, T, 2000) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| "particularly type 2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and cardiovascular complications." | 2.41 | Hepatotoxicity with thiazolidinediones: is it a class effect? ( Scheen, AJ, 2001) |
| "Troglitazone is a valuable addition to the arsenal of antidiabetic drugs for type 2 diabetes." | 2.40 | Troglitazone. Is it all over? ( Hoekstra, JB; Kuck, EM; Wagenaar, LJ, 1999) |
| " Peak bile acid increases occurred within 2hours (h) after dosing and returned to baseline values before 24h." | 1.48 | Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition. ( An, L; Andaya, R; Cepa, S; Maher, J; Morgan, R; Pang, J; Potter, D; Ran, Y; Salphati, L; Schutt, L; Tarrant, J; Wong, L; Zhang, X, 2018) |
| "Troglitazone (Tro) is a thiazolidinedione antidiabetic drug that was withdrawn from the market due to its association with idiosyncratic severe liver injury." | 1.38 | Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. ( Kakuni, M; Katoh, Y; Matsuo, K; Morita, M; Nakajima, M; Tateno, C; Yokoi, T, 2012) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| "Troglitazone was daily administered for 4 weeks (0, 10 or 30 mg/kg/day, ip)." | 1.34 | Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. ( Boelsterli, UA; Latchoumycandane, C; Ong, MM, 2007) |
| "Troglitazone is a thiazolidinedione antidiabetic agent with insulin-sensitizing activities that was withdrawn from the market in 2000 due to its association with idiosyncratic hepatotoxicity." | 1.33 | Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. ( Kaneko, S; Katoh, K; Maniratanachote, R; Nakajima, M; Sawazaki, T; Shibata, A; Tokudome, S; Wakasugi, T; Yamamori, I; Yokoi, T, 2005) |
| "Acute liver failure was defined as acute liver disease and (1) hepatic encephalopathy, (2) prothrombin time prolongation greater than 3 seconds or international normalized ratio greater than 1." | 1.32 | A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. ( Ackerson, L; Chan, KA; Everhart, JE; Gurwitz, JH; Hurley, JS; Martinson, B; Moseley, RH; Platt, R; Selby, JV; Terrault, N; Truman, A, 2003) |
| "Troglitazone is a 2,4-thiazolidinedione antidiabetic agent with insulin-sensitizing activities." | 1.32 | A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. ( Furukawa, H; Haruyama, H; Izumi, T; Koga, T; Koishi, R; Matsushita, Y; Miyoshi, K; Nakamura, K; Shimizu, M; Sugawara, M; Takahashi, T; Tomita, A; Watanabe, I; Yasumo, H, 2003) |
| "Troglitazone (TRG) is an antidiabetic agent that increases the insulin sensitivity of target tissues in non-insulin-dependent diabetes mellitus." | 1.32 | Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism. ( Bharadwaj, LA; Davies, GF; Ovsenek, N; Roesler, WJ, 2003) |
| "Troglitazone is a thiazolidinedione insulin sensitizer drug that is metabolized mainly to a sulfate conjugate (M-1) in humans." | 1.32 | Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. ( Goto, A; Nakajima, M; Nezu, J; Nozawa, T; Sugiura, S; Tamai, I; Tsuji, A; Yokoi, T, 2004) |
| "Troglitazone use was associated with a marked increase in risk of hospitalized acute idiopathic liver injury and ALF." | 1.32 | Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. ( Drinkard, CR; Graham, DJ; Shatin, D, 2003) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 1.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| "Troglitazone was effective in 394 (75%) of the 529 patients for whom an opinion was given." | 1.31 | Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting. ( Biswas, P; Shakir, SA; Wilton, LV, 2001) |
| " In addition, we found that rosiglitazone, although less toxic in the study population, was cytotoxic to hepatocytes in some donors (EC(50)<100 microM)." | 1.31 | Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. ( Fackett, A; Hayden, MJ; Hewitt, NJ; Li, AP; Lloyd, S; Sakai, Y; Silber, PM, 2002) |
| "Rosiglitazone was discontinued, and the patient was treated with prednisone, azathioprine, and ursodiol." | 1.31 | Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. ( Azar, R; Banner, B; Bird, S; Bonkovsky, HL; Szabo, G, 2002) |
| " We studied the effects of TRZ on the hepatotoxicity of carbon tetrachloride (CCl(4)) and acetaminophen (APAP) in rats, both of which exert their toxic effects through bioactivation associated with cytochrome P450 3A (CYP3A) and 2E1 (CYP2E1)." | 1.31 | Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats. ( Kaneko, T; Li, J; Qin, LQ; Sato, A; Wang, PY; Wang, Y, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (11.21) | 18.2507 |
| 2000's | 55 (51.40) | 29.6817 |
| 2010's | 36 (33.64) | 24.3611 |
| 2020's | 4 (3.74) | 2.80 |
| Authors | Studies |
|---|---|
| Nozawa, T | 1 |
| Sugiura, S | 1 |
| Nakajima, M | 3 |
| Goto, A | 1 |
| Yokoi, T | 5 |
| Nezu, J | 1 |
| Tsuji, A | 1 |
| Tamai, I | 1 |
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 3 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Dawson, S | 1 |
| Stahl, S | 2 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Chen, Y | 3 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Aleo, MD | 1 |
| Luo, Y | 1 |
| Swiss, R | 1 |
| Bonin, PD | 1 |
| Potter, DM | 1 |
| Will, Y | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Norman, BH | 1 |
| Wei, H | 1 |
| Li, AP | 2 |
| Chang, JH | 1 |
| Sangaraju, D | 1 |
| Liu, N | 1 |
| Jaochico, A | 1 |
| Plise, E | 1 |
| Dirven, H | 1 |
| Vist, GE | 1 |
| Bandhakavi, S | 1 |
| Mehta, J | 1 |
| Fitch, SE | 1 |
| Pound, P | 1 |
| Ram, R | 1 |
| Kincaid, B | 1 |
| Leenaars, CHC | 1 |
| Wright, RA | 1 |
| Tsaioun, K | 1 |
| Sato, T | 1 |
| Takemura, A | 1 |
| Ito, K | 2 |
| Ware, BR | 1 |
| McVay, M | 1 |
| Sunada, WY | 1 |
| Khetani, SR | 1 |
| Ogimura, E | 1 |
| Nakagawa, T | 1 |
| Deguchi, J | 2 |
| Sekine, S | 1 |
| Bando, K | 1 |
| Mak, A | 1 |
| Kato, R | 1 |
| Weston, K | 1 |
| Hayes, A | 1 |
| Uetrecht, J | 1 |
| Cepa, S | 1 |
| Potter, D | 1 |
| Wong, L | 1 |
| Schutt, L | 1 |
| Tarrant, J | 1 |
| Pang, J | 1 |
| Zhang, X | 1 |
| Andaya, R | 1 |
| Salphati, L | 1 |
| Ran, Y | 1 |
| An, L | 1 |
| Morgan, R | 1 |
| Maher, J | 1 |
| Xu, Q | 1 |
| Liu, L | 1 |
| Vu, H | 1 |
| Kuhls, M | 1 |
| Aslamkhan, AG | 1 |
| Liaw, A | 1 |
| Yu, Y | 1 |
| Kaczor, A | 1 |
| Ruth, M | 1 |
| Wei, C | 1 |
| Imredy, J | 1 |
| Lebron, J | 1 |
| Pearson, K | 1 |
| Gonzalez, R | 1 |
| Mitra, K | 1 |
| Sistare, FD | 1 |
| Jia, R | 1 |
| Oda, S | 1 |
| Tsuneyama, K | 1 |
| Urano, Y | 1 |
| Han, W | 1 |
| Ding, M | 1 |
| Liu, S | 1 |
| Duan, Z | 1 |
| Yang, K | 2 |
| Woodhead, JL | 2 |
| Watkins, PB | 4 |
| Howell, BA | 2 |
| Brouwer, KL | 3 |
| Shon, J | 1 |
| Abernethy, DR | 1 |
| Pfeifer, ND | 1 |
| Köck, K | 1 |
| Goto, S | 1 |
| Nishio, N | 1 |
| Nomura, N | 1 |
| Funabashi, H | 1 |
| Goda, K | 1 |
| Takahashi, T | 2 |
| Kobayashi, A | 1 |
| Shoda, T | 1 |
| Kuno, H | 1 |
| Sugai, S | 1 |
| Siler, SQ | 1 |
| Shoda, LKM | 1 |
| Jemnitz, K | 1 |
| Veres, Z | 1 |
| Vereczkey, L | 1 |
| Ikeda, T | 4 |
| Marion, TL | 1 |
| Perry, CH | 1 |
| St Claire, RL | 1 |
| Yue, W | 1 |
| Boitier, E | 1 |
| Amberg, A | 1 |
| Barbié, V | 1 |
| Blichenberg, A | 1 |
| Brandenburg, A | 1 |
| Gmuender, H | 1 |
| Gruhler, A | 1 |
| McCarthy, D | 1 |
| Meyer, K | 1 |
| Riefke, B | 1 |
| Raschke, M | 1 |
| Schoonen, W | 1 |
| Sieber, M | 1 |
| Suter, L | 1 |
| Thomas, CE | 1 |
| Sajot, N | 1 |
| Matsumoto, K | 1 |
| Hadi, M | 1 |
| Starokozhko, V | 1 |
| Merema, MT | 1 |
| Groothuis, GM | 1 |
| Kakuni, M | 1 |
| Morita, M | 1 |
| Matsuo, K | 1 |
| Katoh, Y | 1 |
| Tateno, C | 1 |
| Kim, JA | 1 |
| Han, E | 1 |
| Eun, CJ | 1 |
| Tak, YK | 1 |
| Song, JM | 1 |
| Bonkovsky, HL | 1 |
| Azar, R | 1 |
| Bird, S | 1 |
| Szabo, G | 1 |
| Banner, B | 1 |
| Lloyd, S | 1 |
| Hayden, MJ | 1 |
| Sakai, Y | 1 |
| Fackett, A | 1 |
| Silber, PM | 1 |
| Hewitt, NJ | 1 |
| Graham, DJ | 2 |
| Drinkard, CR | 1 |
| Shatin, D | 1 |
| Kaplowitz, N | 3 |
| Lewis, JH | 2 |
| Chan, KA | 1 |
| Truman, A | 1 |
| Gurwitz, JH | 1 |
| Hurley, JS | 1 |
| Martinson, B | 1 |
| Platt, R | 1 |
| Everhart, JE | 1 |
| Moseley, RH | 1 |
| Terrault, N | 1 |
| Ackerson, L | 1 |
| Selby, JV | 1 |
| Green, L | 1 |
| Senior, JR | 2 |
| Nourjah, P | 1 |
| Watanabe, I | 1 |
| Tomita, A | 1 |
| Shimizu, M | 1 |
| Sugawara, M | 1 |
| Yasumo, H | 1 |
| Koishi, R | 1 |
| Miyoshi, K | 1 |
| Nakamura, K | 1 |
| Izumi, T | 1 |
| Matsushita, Y | 1 |
| Furukawa, H | 1 |
| Haruyama, H | 1 |
| Koga, T | 1 |
| Davies, GF | 1 |
| Roesler, WJ | 1 |
| Ovsenek, N | 1 |
| Bharadwaj, LA | 1 |
| Smith, MT | 1 |
| Tolman, KG | 2 |
| Chandramouli, J | 1 |
| Lee, WM | 1 |
| Hug, H | 1 |
| Dannecker, R | 1 |
| Schindler, R | 1 |
| Bagatto, D | 1 |
| Stephan, A | 1 |
| Wess, RA | 1 |
| Gut, J | 1 |
| Chojkier, M | 1 |
| Maddrey, WC | 1 |
| Caldefie-Chézet, F | 1 |
| Poulin, A | 1 |
| Enreille-Leger, A | 1 |
| Vasson, MP | 1 |
| Maniratanachote, R | 1 |
| Shibata, A | 1 |
| Kaneko, S | 1 |
| Yamamori, I | 1 |
| Wakasugi, T | 1 |
| Sawazaki, T | 1 |
| Katoh, K | 1 |
| Tokudome, S | 1 |
| Slavin, DE | 1 |
| Schlichting, CL | 1 |
| Freston, JW | 1 |
| Temple, R | 1 |
| Hastings, KL | 1 |
| Masubuchi, Y | 1 |
| Ong, MM | 1 |
| Latchoumycandane, C | 1 |
| Boelsterli, UA | 1 |
| Jaeschke, H | 1 |
| Wolbert, CJ | 1 |
| Kanazawa, A | 1 |
| Kawamori, R | 1 |
| Murata, Y | 1 |
| Onji, M | 1 |
| Nightingale, SL | 1 |
| Imura, H | 1 |
| Whitcomb, RW | 1 |
| Gitlin, N | 1 |
| Julie, NL | 1 |
| Spurr, CL | 1 |
| Lim, KN | 1 |
| Juarbe, HM | 1 |
| Vella, A | 1 |
| de Groen, PC | 1 |
| Dinneen, SF | 1 |
| Misbin, RI | 1 |
| Wagenaar, LJ | 1 |
| Kuck, EM | 1 |
| Hoekstra, JB | 1 |
| Iwase, M | 1 |
| Yamaguchi, M | 1 |
| Yoshinari, M | 1 |
| Okamura, C | 1 |
| Hirahashi, T | 1 |
| Tsuji, H | 1 |
| Fujishima, M | 1 |
| Zurlinden, J | 1 |
| Booth, AM | 1 |
| Caldwell, SH | 3 |
| Iezzoni, JC | 1 |
| Malik, AH | 1 |
| Prasad, P | 1 |
| Saboorian, MH | 1 |
| Thiele, DL | 1 |
| Malet, PF | 1 |
| Kuzuya, T | 1 |
| Toyota, T | 1 |
| Ueno, Y | 1 |
| Scheen, AJ | 2 |
| Paquot, N | 1 |
| Letiexhe, MR | 1 |
| Lefèbvre, PJ | 1 |
| Jagannath, S | 1 |
| Rai, R | 1 |
| Schiano, T | 1 |
| Dolehide, K | 1 |
| Hart, J | 1 |
| Baker, AL | 1 |
| Bell, DS | 1 |
| Ovalle, F | 1 |
| Everett, L | 1 |
| Galli, A | 1 |
| Crabb, D | 1 |
| Krentz, AJ | 1 |
| Bailey, CJ | 1 |
| Melander, A | 1 |
| Arioglu, E | 1 |
| Duncan-Morin, J | 1 |
| Sebring, N | 1 |
| Rother, KI | 1 |
| Gottlieb, N | 1 |
| Lieberman, J | 1 |
| Herion, D | 1 |
| Kleiner, DE | 1 |
| Reynolds, J | 1 |
| Premkumar, A | 1 |
| Sumner, AE | 1 |
| Hoofnagle, J | 1 |
| Reitman, ML | 1 |
| Taylor, SI | 1 |
| Prendergast, KA | 1 |
| Berg, CL | 1 |
| Wisniewski, R | 1 |
| Lenhard, MJ | 1 |
| Funk, WB | 1 |
| Donnelly, R | 1 |
| Biswas, P | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Gottlieb, S | 1 |
| Hespenheide, EE | 1 |
| von Borstel, RW | 1 |
| Angulo, P | 1 |
| Lindor, KD | 1 |
| Gale, EA | 1 |
| Kobayashi, M | 1 |
| Iwata, M | 1 |
| Li, J | 1 |
| Kaneko, T | 1 |
| Wang, Y | 1 |
| Qin, LQ | 1 |
| Wang, PY | 1 |
| Sato, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity[NCT02353455] | 300 participants (Anticipated) | Observational | 2013-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
28 reviews available for troglitazone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Eval | 2020 |
Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Drug-Related Side Effects and Adverse Rea | 2021 |
The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury.
Topics: Animals; Benzazepines; Chemical and Drug Induced Liver Injury; Chromans; Drug-Related Side Effects a | 2017 |
Troglitazone.
Topics: Biotransformation; Chemical and Drug Induced Liver Injury; Chromans; Drug Hypersensitivity; Humans; | 2010 |
Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Biotransformation; Chemical and Drug Induced Liver Injur | 2011 |
[Drug-induced hepatic injury, the challenge for cause investigation].
Topics: Animals; Apoptosis; Benzbromarone; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chromans | 2011 |
[Idiosyncratic drug toxicity].
Topics: Adaptive Immunity; Animals; Chemical and Drug Induced Liver Injury; Chromans; Cytochrome P-450 Enzym | 2012 |
Mechanisms of troglitazone hepatotoxicity.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Models, Anim | 2003 |
Hepatotoxicity of the thiazolidinediones.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; | 2003 |
Drug-induced hepatotoxicity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Chemical and Drug Induced Liv | 2003 |
Ontology-based knowledge management of troglitazone-induced hepatotoxicity.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Chemical and Drug Induced Liver Inju | 2004 |
Troglitazone and liver injury: in search of answers.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver; Thiaz | 2005 |
Drug-induced hepatotoxicity: 2005.
Topics: Acetaminophen; Chemical and Drug Induced Liver Injury; Chromans; Female; Humans; Hydroxymethylglutar | 2005 |
[Drug-induced liver injury].
Topics: Acetaminophen; Anesthetics, General; Animals; Benzoquinones; Chemical and Drug Induced Liver Injury; | 2006 |
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Cytochrome P-450 CYP3A; Glut | 2006 |
[Adverse effects of insulin sensitisers and biguanides].
Topics: Acidosis, Lactic; Animals; Biguanides; Capillary Permeability; Chemical and Drug Induced Liver Injur | 2007 |
[Abnormality of liver functional test in patients with drug-induced liver injury].
Topics: Acetaminophen; Analgesics; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cardiovas | 2007 |
Troglitazone. Is it all over?
Topics: Animals; Blood Glucose; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; | 1999 |
Hepatic injury due to troglitazone.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypogly | 2000 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellit | 2000 |
[Clinical effect and side effect of troglitazone].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Huma | 2000 |
[Thiazolidinediones].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag | 1999 |
The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Fatty Liver, Alcoholic; Kupffer Cells; Li | 2000 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes | 2001 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, | 2001 |
Thiazolidinedione hepatotoxicity: a class effect?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag | 2000 |
1 trial available for troglitazone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.
Topics: Adipose Tissue; Adult; Aged; Body Composition; Chemical and Drug Induced Liver Injury; Child; Chroma | 2000 |
78 other studies available for troglitazone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
Topics: Biological Transport, Active; Chemical and Drug Induced Liver Injury; Chromans; Cloning, Molecular; | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2014 |
Permeabilized Cryopreserved Human Hepatocytes as an Exogenous Metabolic System in a Novel Metabolism-Dependent Cytotoxicity Assay for the Evaluation of Metabolic Activation and Detoxification of Drugs Associated with Drug-Induced Liver Injuries: Results w
Topics: Acetaminophen; Activation, Metabolic; Amiodarone; Chemical and Drug Induced Liver Injury; Cyclophosp | 2022 |
Comprehensive Evaluation of Bile Acid Homeostasis in Human Hepatocyte Co-Culture in the Presence of Troglitazone, Pioglitazone, and Acetylsalicylic Acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Acids and Salts; Cells, Cultured; Chemical an | 2019 |
Role of respiratory uncoupling in drug-induced mitochondrial permeability transition.
Topics: Animals; Chemical and Drug Induced Liver Injury; Hypoglycemic Agents; Male; Mitochondria, Liver; Mit | 2021 |
Exploring Chronic Drug Effects on Microengineered Human Liver Cultures Using Global Gene Expression Profiling.
Topics: 3T3 Cells; Animals; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chromans; Coculture Tec | 2017 |
Troglitazone Inhibits Bile Acid Amidation: A Possible Risk Factor for Liver Injury.
Topics: Amides; Bile Acids and Salts; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chromans; Hum | 2017 |
Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.
Topics: Animals; Antibodies, Monoclonal; Catechols; Cell Line; Chemical and Drug Induced Liver Injury; CTLA- | 2018 |
Individual serum bile acid profiling in rats aids in human risk assessment of drug-induced liver injury due to BSEP inhibition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Bile Acids and Salts; Chemical an | 2018 |
Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the
Topics: Amiodarone; Benzbromarone; Chemical and Drug Induced Liver Injury; Galactose; Glucose; Hep G2 Cells; | 2019 |
Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism.
Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Female; Hypoglycemic Agents | 2019 |
Evaluation of 3D re-cellularized tissue engineering: a drug-induced hepatotoxicity model for hepatoprotectant research.
Topics: Animals; Cell Survival; Chemical and Drug Induced Liver Injury; Diclofenac; Gene Expression; Hep G2 | 2019 |
Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity.
Topics: Alanine Transaminase; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding | 2014 |
Application of systems pharmacology to explore mechanisms of hepatotoxicity.
Topics: Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemi | 2014 |
Species differences in hepatobiliary disposition of taurocholic acid in human and rat sandwich-cultured hepatocytes: implications for drug-induced liver injury.
Topics: Adult; Animals; Bile Ducts; Biological Transport; Cells, Cultured; Chemical and Drug Induced Liver I | 2015 |
Hepatotoxicants induce cytokine imbalance in response to innate immune system.
Topics: Acetaminophen; Animals; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chemokines; Chroman | 2015 |
Usefulness of in vitro combination assays of mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury.
Topics: Acetaminophen; Apoptosis; Biological Assay; Biomarkers; Caspase 3; Caspase 7; Cells, Cultured; Chemi | 2016 |
Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes.
Topics: Animals; ATP-Binding Cassette Transporters; Biological Transport; Carbon Radioisotopes; Cells, Cultu | 2011 |
A comparative integrated transcript analysis and functional characterization of differential mechanisms for induction of liver hypertrophy in the rat.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Gene Expression Profiling; Gene Regulator | 2011 |
Mouse precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury.
Topics: Animals; Benzodiazepines; Biomarkers; Carbamazepine; Cell Survival; Chemical and Drug Induced Liver | 2012 |
Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury.
Topics: Animals; Antineoplastic Agents; Buthionine Sulfoximine; Chemical and Drug Induced Liver Injury; Chro | 2012 |
Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity.
Topics: Apoptosis; Benzophenones; Calcium; Caspase 3; Chemical and Drug Induced Liver Injury; Chromans; Hep | 2012 |
Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.
Topics: Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Female; Humans; | 2002 |
Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors.
Topics: Adenosine Triphosphate; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; C | 2002 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type | 2002 |
Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.
Topics: Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Chromans; Female; Hospitalization; | 2003 |
Did this drug cause my patient's hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postma | 2003 |
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.
Topics: Acute Disease; Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; Cohort Studies; Female | 2003 |
Troglitazone-induced liver failure: a case study.
Topics: Age Distribution; Aged; Chemical and Drug Induced Liver Injury; Chromans; Chronic Disease; Confidenc | 2003 |
A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Alanine Transaminase; Alleles; Aspartate Aminotransferases; Chemical and Drug Induced Liver In | 2003 |
Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism.
Topics: Acetylcysteine; Animals; Blotting, Northern; Blotting, Western; Cells, Cultured; Chemical and Drug I | 2003 |
Troglitazone reduces leptinemia during experimental dexamethasone-induced stress.
Topics: Adipocytes; Adipose Tissue; Animals; Anorexia; Blood Glucose; Body Weight; Chemical and Drug Induced | 2005 |
Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction.
Topics: Aged; Alanine Transaminase; Autoantibodies; Chemical and Drug Induced Liver Injury; Chromans; Diabet | 2005 |
Rating the severity of the medical consequences of drug-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Data Collection; Humans; Hypoglycemic Agents; Live | 2005 |
'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.
Topics: Alanine Transaminase; Anticoagulants; Azetidines; Benzylamines; Bilirubin; Biomarkers; Chemical and | 2006 |
Hy's law: predicting serious hepatotoxicity.
Topics: Adverse Drug Reaction Reporting Systems; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroid | 2006 |
Rules and laws of drug hepatotoxicity.
Topics: Adverse Drug Reaction Reporting Systems; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroid | 2006 |
How can 'Hy's law' help the clinician?
Topics: Adverse Drug Reaction Reporting Systems; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroid | 2006 |
The use of hepatotoxic signals to predict the safety of peroxisome proliferator-activated receptor agonists.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Humans; Hypogly | 2006 |
Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.
Topics: Aconitate Hydratase; Animals; Chemical and Drug Induced Liver Injury; Chromans; Disease Models, Anim | 2007 |
SNP communications: coalition of toxicology and drug metabolism and pharmacokinetics.
Topics: Animals; Biotransformation; Chemical and Drug Induced Liver Injury; Chromans; Drug-Related Side Effe | 2007 |
Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Disease Models, Animal; Humans; Hypoglyce | 2007 |
Tort law: Desiano and the Second Circuit's repudiation of de jure tort reform.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Ind | 2007 |
From the Food and Drug Administration.
Topics: Appetite Depressants; Chemical and Drug Induced Liver Injury; Chromans; Drug Labeling; Fenfluramine; | 1997 |
A novel antidiabetic drug, troglitazone--reason for hope and concern.
Topics: Administration, Oral; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; H | 1998 |
Hepatic dysfunction associated with troglitazone.
Topics: Alanine Transaminase; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus; Female; H | 1998 |
Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 1; Diabetes M | 1998 |
Fatal hepatotoxicity associated with troglitazone.
Topics: Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2 | 1998 |
Troglitazone-associated hepatic failure.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidi | 1999 |
A Japanese case of liver dysfunction after 19 months of troglitazone treatment.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Female; Humans; Hypoglycemic Agents; Japan; Middle | 1999 |
Avoiding hepatic injury from drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Chemical and Drug Induced Liv | 1999 |
Rezulin pulled in the UK.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Drug and Narcotic Control; Humans; Hypoglycemic Ag | 1998 |
Troglitazone-associated hepatic failure.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Fatal Outcome; Fe | 2000 |
Rapid-onset subfulminant liver failure associated with troglitazone.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; | 2000 |
Severe but reversible hepatitis induced by troglitazone.
Topics: Biopsy; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypogly | 2000 |
Substituting for troglitazone (Rezulin).
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag | 2000 |
Late-onset troglitazone-induced hepatic dysfunction.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglyce | 2000 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug | 2000 |
Troglitazone-associated hepatotoxicity treated successfully with steroids.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Chromans; Humans; P | 2000 |
Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Female; Humans; | 2001 |
FDA reviews troglitazone.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Ag | 1999 |
Troglitazone and liver function abnormalities: lessons from a prescription event monitoring study and spontaneous reporting.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; England; Fatigue; Female; Humans; Hyp | 2001 |
Company played down drug's risks, report says.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Deception; Diabetes Mellitus, Type 2; Dru | 2001 |
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Chromans; Diab | 2001 |
Efficacy and safety of troglitazone for lipodystrophy syndromes.
Topics: Adipocytes; Chemical and Drug Induced Liver Injury; Chromans; Hepatocytes; Humans; Lipodystrophy; Mi | 2001 |
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Topics: Adult; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fat | 2001 |
Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYP3A in rats.
Topics: Acetaminophen; Administration, Oral; Animals; Aryl Hydrocarbon Hydroxylases; Carbon Tetrachloride; C | 2002 |